12 Week Efficacy and Safety Study of Empagliflozin (BI 10773) in Hypertensive Patients With Type 2 Diabetes Mellitus

NCT01370005 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

825

Enrollment

INDUSTRY

Sponsor class

Conditions

Diabetes Mellitus, Type 2
Hypertension

Interventions

DRUG: Placebo
DRUG: BI 10773
DRUG: Placebo
DRUG: BI 10773
DRUG: Placebo
DRUG: Placebo

Sponsor

Boehringer Ingelheim

Collaborators

[object Object]